Your browser doesn't support javascript.
loading
Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation.
Yin, Yi; Li, Rui; Xu, Kangling; Ding, Sentai; Li, Jeffrey; Baek, GuemHee; Ramanand, Susmita G; Ding, Sam; Liu, Zhao; Gao, Yunpeng; Kanchwala, Mohammed S; Li, Xiangyi; Hutchinson, Ryan; Liu, Xihui; Woldu, Solomon L; Xing, Chao; Desai, Neil B; Feng, Felix Y; Burma, Sandeep; de Bono, Johann S; Dehm, Scott M; Mani, Ram S; Chen, Benjamin P C; Raj, Ganesh V.
Affiliation
  • Yin Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. Yi.Yin@utsouthwestern.edu Ganesh.Raj@utsouthwestern.edu.
  • Li R; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Xu K; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Ding S; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Li J; Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China.
  • Baek G; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Ramanand SG; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Ding S; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Liu Z; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Gao Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Kanchwala MS; Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China.
  • Li X; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Hutchinson R; Eugene McDermott Center for Human Growth & Development, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Liu X; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Woldu SL; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Xing C; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Desai NB; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Feng FY; Eugene McDermott Center for Human Growth & Development, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Burma S; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • de Bono JS; Department of Radiation Oncology, University of California at San Francisco, San Francisco, California.
  • Dehm SM; Department of Urology, University of California at San Francisco, San Francisco, California.
  • Mani RS; Department of Medicine, University of California at San Francisco, San Francisco, California.
  • Chen BPC; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Raj GV; Drug Development Unit and Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom.
Cancer Res ; 77(18): 4745-4754, 2017 09 15.
Article in En | MEDLINE | ID: mdl-28754673
In prostate cancer, androgen deprivation therapy (ADT) enhances the cytotoxic effects of radiotherapy. This effect is associated with weakening of the DNA damage response (DDR) normally supported by the androgen receptor. As a significant number of patients will fail combined ADT and radiotherapy, we hypothesized that DDR may be driven by androgen receptor splice variants (ARV) induced by ADT. Investigating this hypothesis, we found that ARVs increase the clonogenic survival of prostate cancer cells after irradiation in an ADT-independent manner. Notably, prostate cancer cell irradiation triggers binding of ARV to the catalytic subunit of the critical DNA repair kinase DNA-PK. Pharmacologic inhibition of DNA-PKc blocked this interaction, increased DNA damage, and elevated prostate cancer cell death after irradiation. Our findings provide a mechanistic rationale for therapeutic targeting of DNA-PK in the context of combined ADT and radiotherapy as a strategy to radiosensitize clinically localized prostate cancer. Cancer Res; 77(18); 4745-54. ©2017 AACR.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Receptors, Androgen / Protein Kinase Inhibitors / DNA Repair / DNA-Activated Protein Kinase / Androgen Antagonists Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: Cancer Res Year: 2017 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Receptors, Androgen / Protein Kinase Inhibitors / DNA Repair / DNA-Activated Protein Kinase / Androgen Antagonists Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: Cancer Res Year: 2017 Document type: Article Country of publication: United States